Clinical trial
A Safety and Pharmacokinetics Study in Participants With Rheumatoid Arthritis
NCT00380744 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00380744 |
|---|---|
| Title | A Safety and Pharmacokinetics Study in Participants With Rheumatoid Arthritis |
| Official title | A Phase 1b/2 Multiple-Dose Safety Study and Pharmacokinetic/ Pharmacodynamic Study of LY2189102 in Patients With Rheumatoid Arthritis |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Arthritis, Rheumatoid |
| Intervention type | Drug |
| Interventions | LY2189102, placebo |
| Enrollment | 121 |
| Start date | Nov 1, 2005 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Sep 26, 2006 |
| Last update posted | Feb 6, 2019 |
| Countries | Poland, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: